Abstract
Thiosemicarbazones are potential anticancer agents. In this study, we designed and synthesized new thiosemicarbazone derivatives as anticancer agents. The antiproliferative activity of compounds (IIIa, IIIb, IIIe, IIIh, and IIIi) selected by The National Cancer Institute (USA) was investigated in vitro in 60 cancer cell lines. The initial results of the screening of these compounds revealed encouraging anticancer activity. The enzyme inhibitory activity of the compounds against ribonucleotide reductase was then evaluated. It was found that compounds IIIa, IIIe, and IIIh show the most potent inhibitory activity with IC50 (1.51, 2.41, and 2.85 μM, respectively). Flow cytometric analysis showed that compound IIIa induced apoptosis and cell cycle arrest in the G2/M phase. Additionally, according to the gene expression report, compound IIIa upregulated p53, BAX, and caspase-3 expression and down regulated Bcl-2 expression. Thus, IIIa exerted potent inhibitory activity against RNR and a strong pro-apoptotic effect by activating the intrinsic apoptotic pathway.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
